Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Cordis' sirolimus-eluting balloon gets FDA approval for coronary in-stent restenosis

24 September 2026 · By · Wire by Fusion42

Published

24 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at med-tech.world →

◆ Verified

Fusion42 · 24 September 2026 · Fusion42 review

The U.S. FDA has approved Cordis’ SELUTION SLR sirolimus-eluting balloon for treating coronary in-stent restenosis, offering a non-stent drug delivery alternative for arteries that narrow after stent placement.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 22 Sep 2026 and 28 Sep 2026.

◆ ◆ The Wire takeaway

You gain an FDA-cleared sirolimus balloon option that limits permanent implants in coronary arteries. This shift opens opportunity to compete where adding stents is clinically discouraged.

◆ Coverage

3 sources · first reported 22 Sep 2026 · latest 28 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalcardiovasculardrug-eluting-balloonsirolimusin-stent-restenosis